# BILIX Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bilix-co

- Industry: Biotechnology
- Headquarters: Yongin, South Korea
- Website: www.bilix.com/
- Total disclosed funding: $20M
- Latest round: Series B (Apr 16, 2026)
- Investors on record: 12

## About

Founded in 2018 in Yongin, South Korea, BILIX Co., Ltd. focuses on advancing therapeutic solutions through its proprietary technologies. Myung-lip Kim, who has a history of founding innovative biotech ventures, serves as both CEO and founder. In April 2026, BILIX Co., Ltd. raised KRW 11.25 billion in series B funding from new investors DreamCIS, Evergreen Investment Partners, iM Investment Partners, and Minetta Brook Ventures. Returning investors DS Asset Management, SoulBrain Co., Ltd., and Daekyo Investment also participated in this round.

BILIX specializes in developing innovative therapeutic solutions based on its proprietary PEGylated bilirubin platform technology, known as Brixelle®. This flagship product utilizes the antioxidant properties of bilirubin combined with polyethylene glycol (PEG) to create novel treatments for oxidative stress and inflammation. Brixelle® is formulated into a nanoparticle delivery system for applications in treating intractable inflammatory diseases and enhancing anti-cancer drug delivery. The technology has attracted interest from pharmaceutical partners and research institutions in Asia, Europe, and North America, aiming to serve healthcare providers and research organizations.

BILIX's revenue model is primarily based on partnerships and collaborations with research organizations and healthcare institutions. The company engages in joint research and development efforts which might include licensing agreements and co-development contracts for its products. The Brixelle® platform may be provided to clinical partners in exchange for milestone payments and royalties on future sales. As the company approaches commercialization, revenue generation is anticipated from both B2B transactions with pharmaceutical firms and potential direct-to-consumer applications once products are launched.

The company is targeting expansion into key markets across Asia, Europe, and North America, with a timeline for market entry contingent on the successful completion of ongoing research and product development initiatives. The funding in April 2026 will support the company to commence clinical trials for its pipeline.

## Funding rounds

- Series B, Apr 16, 2026, $7.6M — Daekyo Investment, Evergreen Investment Partners, SoulBrain Co., Ltd., DreamCIS, iM Investment Partners, DS Asset Management, Minetta Brook Ventures
- Series A, May 25, 2021, $12M — Industrial Bank of Korea, Magna Investment, SoulBrain Co., Ltd., Genaxis, We Ventures, DS Asset Management, Polaris AI Pharma Corp.

## Investors

- Industrial Bank of Korea — Series A
- Magna Investment (https://capitalatlas.ai/funds/magna-investment) — Series A
- SoulBrain Co., Ltd. — Series A, Series B
- Genaxis (https://capitalatlas.ai/funds/genaxis) — Series A
- We Ventures — Series A
- DS Asset Management (https://capitalatlas.ai/funds/ds-asset-management) — Series A, Series B
- Polaris AI Pharma Corp. — Series A
- Daekyo Investment (https://capitalatlas.ai/funds/daekyo-investment) — Series B
- Evergreen Investment Partners (https://capitalatlas.ai/funds/evergreen-investment-partners) — Series B
- DreamCIS — Series B
- iM Investment Partners (https://capitalatlas.ai/funds/im-investment-partners) — Series B
- Minetta Brook Ventures (https://capitalatlas.ai/funds/minetta-brook-ventures) — Series B